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†School of Systems Biology, George Mason University, Manassas, Virginia; and ‡The MITRE Corporation, San Diego, CaliforniaABSTRACT Experimental and epidemiological studies have shown that the nonsteroidal antiinflammatory drug naproxen may
be useful in the treatment of Alzheimer’s disease. To investigate the interactions of naproxen with Ab dimers, which are the
smallest cytotoxic aggregated Ab peptide species, we use united atom implicit solvent model and exhaustive replica exchange
molecular dynamics. We show that naproxen ligands bind to Ab dimer and penetrate its volume interfering with the interpeptide
interactions. As a result naproxen induces a destabilizing effect on Ab dimer. By comparing the free-energy landscapes of
naproxen interactions with Ab dimers and fibrils, we conclude that this ligand has stronger antiaggregation potential against
Ab fibrils rather than against dimers. The analysis of naproxen binding energetics shows that the location of ligand binding sites
in Ab dimer is dictated by the Ab amino acid sequence. Comparison of the in silico findings with experimental observations
reveals potential limitations of naproxen as an effective therapeutic agent in the treatment of Alzheimer’s disease.INTRODUCTIONA number of age-related disorders, including Alzheimer’s,
Parkinson’s, and Creutzfeldt-Jakob diseases, are associated
with aberrant aggregation of polypeptide chains and forma-
tion of amyloid fibrils (1,2). Biomedical experiments and
genetic studies suggested that the onset of Alzheimer’s
disease (AD) is related to aggregation of Ab peptides (3),
which are derived from the transmembrane amyloid pre-
cursor protein in the course of proteolysis. Although these
peptides have varying lengths, the 40-residue species,
Ab140, are most abundant. Their assembly into amyloid
fibrils involves multiple conformational transitions, in
which oligomeric species appear as intermediates (2,4,5).
It is well known that Ab fibrils are cytotoxic (6), but recent
findings pointed to Ab oligomers as primary cytotoxic
species in AD (7–9). Furthermore, synaptic structure and
function can be impaired even by the smallest Ab oligo-
mers, called dimers (10). According to hydrogen/deuterium
exchange experiments soluble oligomeric species exist in
dynamic equilibrium with amyloid fibrils (11). These obser-
vations implicate a crucial role played by Ab oligomers in
amyloidogenesis.
Recognition of the importance of Ab peptides in AD path-
ogenesis has led to a search of smallmolecular agents that can
inhibit or delay Ab aggregation. One of the potential antiag-
gregation agents is a nonsteroidal antiinflammatory drug
naproxen (12) (Fig. 1 a). Long-term prophylactic use of nap-
roxen may reduce the risk of AD (13–15). Reexamination of
recent large-scale clinical trials revealed that when the
patients with preexisting conditions are removed from
consideration naproxen reduces the AD risk by 67% (12).Submitted December 22, 2010, and accepted for publication February 24,
2011.
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0006-3495/11/04/2024/9 $2.00However, it also appears that this drug offers no therapeutic
effect in preexisting AD cases (16,17). In fact, according to
micemodels naproxen cannot reverse existingADconditions
in brain microglia (18). Several in vitro experimental studies
have probed the interactions of naproxenwithAb aggregates.
In particular, experiments have implicated binding of
naproxen to Ab fibrils (19,20). Furthermore, naproxen has
been shown to reduce the amount of Ab fibrils upon its
coincubation with the fresh Ab monomers or to destabilize,
but not to depolymerize, preformedAbfibrils (19,21). Exper-
iments have also revealed that this nonsteroidal antiinflam-
matory drug interferes with Ab fibril elongation and at a
sufficiently large concentration completely inhibits fibril
growth (21).
Although the antiaggregation effect of naproxen is
documented, the underlying molecular mechanisms are un-
known. In principle, molecular dynamics (MD) simulations
can describe the interactions of Ab species with the ligands
at all-atom resolution (22). In recent years, MD was used to
explore the mechanisms of fibril growth (23–26) and to
investigate the conformational ensembles of amyloidogenic
monomers (27,28) and oligomers (29–33). Recently, we
have initiated a series of MD studies targeting the interac-
tions between Ab fibrils and naproxen ligands (34,35).
We showed that naproxen binding to Ab fibril is mainly
governed by fibril surface geometry rather than by ligand-
peptide interactions. In particular, the primary binding loca-
tion of naproxen appears to be a hydrophobic groove located
on the edge of growing Ab fibril, which is also a preferred
binding site for incoming Ab peptides (26). Consequently,
the antiaggregation effect of naproxen was explained by
direct competition between the ligands and Ab peptides
for the same binding location on the fibril surface.
However, similar investigation of naproxen interactions
with Ab oligomers, which are the most cytotoxic speciesdoi: 10.1016/j.bpj.2011.02.044
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FIGURE 1 (a) Chemical structure of naproxen. Methoxy (G2) and
carboxylate (G3) groups are linked to the central hydrophobic naphthalene
ring (G1). Carbon and oxygen atoms are in gray and red (in online version).
(b) The WT sequence of Ab1040 peptide and the allocation of the N- and
C-terminals (Nt and Ct). In the mutant sequence the order of amino acids is
reversed. (c) Typical structure of Ab dimer coincubated with naproxen
ligands at 360 K. Ab Nt and Ct terminals are shown in red and yellow,
respectively (in online version). Naproxen ligands bind with higher affinity
to the N-terminal, which is also the primary dimer aggregation interface.
Antiaggregation Effect of Naproxen 2025in AD, has not been performed. Therefore, it is not clear if
naproxen destabilizes oligomers or even dissolves them. It is
unknown if this ligand can selectively bind or recognize
specific Ab species, such as oligomers or fibrils. There is
also no information on the location of naproxen binding
sites in Ab oligomers. From a more fundamental viewpoint,
little is known about the physicochemical factors that
control naproxen binding to Ab oligomers, and if these
factors are different from those governing binding to the
fibril.
To answer these questions, we use exhaustive replica
exchange MD (REMD) coupled with implicit solvent united
atom model and study equilibrium interactions of Ab dimers
with naproxen ligands. We show that naproxen destabilizes
Ab dimer by penetrating into its core and interfering with
interpeptide amino acid interactions. Based on the analysis
of ligand binding energetics, we argue that the mechanism
of naproxen binding to Ab oligomer is different from that
observed for the fibril. As a result, the affinity of naproxenbinding to Ab dimer is weaker compared to the fibril. We
conclude with a discussion of naproxen antiaggregation effi-
ciency with respect to different Ab species.METHODS
Simulation model
To simulate Ab peptides coincubated with naproxen (Fig. 1), we used the
CHARMM MD program (36) and united atom force field CHARMM19
coupled with the solvent accessible surface area (SASA) implicit solvent
model (37). The force field description, its applicability, and testing can
be found in our previous studies (31,34,38). In particular, we have shown
that CHARMM19þSASA force field accurately reproduces the experi-
mental distribution of chemical shifts for Ca and Cb atoms in Abmonomers
(31,39). Parameterization of naproxen (Fig. 1 a) in CHARMM19 force field
was developed in the previous study (34). Additional arguments supporting
the use of CHARMM19þSASA force field can be found in the Supporting
Material.
In this work, we use the N-terminal truncated fragment of the full-length
peptide, Ab1040 (Fig. 1 b) (40). The rationale for selecting Ab1040 as
a model of the full-length Ab140 is presented in the Supporting Material.
The simulation system consists of two Ab1040 peptides interacting with 20
naproxen molecules (Fig. 1 c). Peptides and ligands are subject to spherical
boundary condition with the radius Rs ¼ 90 A˚ and the force constant
ks ¼ 10 kcal =mol A2. Consequently, the peptide and naproxen concentra-
tions are z7 and 65 mM. The concentration ratio of naproxen to Ab
peptides, i.e., the ratio of the numbers of ligands and peptides is 10:1, which
is within the range used experimentally (from 1 to 22) (21,41). Selection of
Ab dimer for our simulations is motivated by the experimental observation
that the dimer is the smallest cytotoxic Ab oligomer (10).Replica exchange simulations
We used REMD to perform conformational sampling (42). The description
of REMD implementation can be found in our previous studies (31,43).
Briefly, 24 replicas were distributed linearly in the temperature range from
300 to 530 K with the increment of 10 K. The selected temperature range
spans the spectrum of Ab conformational states from aggregated to disso-
ciate. Due to a small temperature increment the energy distributions from
neighboring replicas share considerable overlap. The exchanges were at-
tempted every 80 ps between all neighboring replicas with the average
acceptance rate of 41%. In all, 13 REMD trajectories were produced result-
ing in the cumulative simulation time of 250 ms. The structures were saved
with the interval of 40 ps, and between replica exchanges the system evolved
using NVT underdamped Langevin dynamics with the damping coefficient
g ¼ 0:15 ps1 and the integration step of 2fs. Because initial parts of REMD
trajectories are not equilibrated, the cumulative equilibrium simulation time
is reduced to tsimz227 ms. All REMD trajectories were started with random
dissociated distributions of peptides and ligands in the sphere.Computation of structural probes
Interactions formed by Ab peptides and naproxen were probed as follows.
A contact between amino acid side chains occurs, if the distance between
their centers of mass is less than 6.5 A˚. This cutoff approximately corre-
sponds to the onset of hydration of side chains as their separation increases.
If a contact involves two apolar amino acids, it is referred to as hydro-
phobic. A dimer is considered formed, if at least one side chain contact
is established between the two peptides. Computations of contacts between
naproxen and Ab are described in the Supporting Material.
The backbone hydrogen bonds (HBs) between peptide NH and CO
groups were assigned according to Kabsch and Sander (44). The sameBiophysical Journal 100(8) 2024–2032
<C(T;w)>
<C(T)>
<Ch(T;w)>
<Ch(T)>
FIGURE 2 Formation of Ab1040 dimer is probed using the temperature
dependencies of the numbers of interpeptide side chain contacts hCðTÞi and
interpeptide hydrophobic contacts hChðTÞi. Data in black and gray corre-
spond to naproxen solution and ligand-free water, respectively. The plot
demonstrates that naproxen interference weakens interpeptide interactions.
2026 Kim et al.definition was applied to detect HBs between naproxen and peptide back-
bone NH groups (34). Secondary structure in Ab peptides was assigned
using the distribution of ðf;jÞ backbone dihedral angles. Definitions of
b-strand and helix states can be found in our earlier studies (31). The
nonbonded energies of interactions between the ligands and between the
ligands and Ab were computed using CHARMM INTERACTION func-
tionality. Definitions of radial distribution functions, gppðrÞ and glpðrÞ,
mapping minimum distances between amino acids and ligands, are given
in the Supporting Material.
In our previous studies, assembly of Ab dimer and Ab fibril growth were
studied in water at a temperature of 360 K, at which incoming Ab peptide
locks into fibril-like state during deposition onto the fibril (26,45). To facil-
itate the assessment of naproxen antiaggregation effect, we report the prop-
erties of Ab dimers coincubated with naproxen at 360 K. However, we
observed no qualitative differences in naproxen interactions with Ab dimer,
if the temperature is reduced to 330 K. To compute thermodynamic aver-
ages of structural quantities and free-energy landscapes the distributions
of states produced by REMD were processed using the multiple histogram
method (46). Throughout the article angular brackets <::> imply thermody-
namic averages. Because dimer includes two indistinguishable peptides,
quantities related to Ab are averaged over two peptides. The convergence
of REMD simulations and error analysis are presented in the Supporting
Material.Analysis of naproxen binding using AutoDock
To provide an independent test of naproxen binding mechanism, we used
a software package AutoDock4.2 (47), which probed the interactions
between Ab peptide and naproxen. Details describing the application of
AutoDock can be found in the Supporting Material.RESULTS
Binding of naproxen and its impact on the stability of Ab
dimer were investigated using REMD simulations (Fig. 1 c).
To assess changes in the structure of Ab dimer and naproxen
binding patterns, it is convenient to define the sequence
regions in Ab peptide. We distinguish the N-terminal (Nt,
residues 10–23), which corresponds to the first b-strand in
the Ab fibril structure (48), and the C-terminal (Ct, residues
29–39), which corresponds to the second fibril b-strand
(Fig. 1 b).Naproxen destabilizes Ab dimer
To examine the assembly of Ab dimer coincubated with
naproxen, we computed the number of interpeptide contacts
hCðTÞi and interpeptide hydrophobic contacts hChðTÞi as
a function of temperature T and compared them with the
same quantities hCðT;wÞi and hChðT;wÞi obtained in water
(45). Fig. 2 shows that hCðTÞi and hCðT;wÞi increase with
the decrease in T and are similar up to TT400 K. At lower
temperatures the number of interpeptide contacts in water
hCðT;wÞi continues its monotonic increase, whereas
hCðTÞi declines. Similar behavior is seen in the temperature
dependence of interpeptide hydrophobic contacts hChðTÞi.
At 360 K the number of interpeptide side chain contacts
in Ab dimer coincubated in naproxen and in water are
hCiz19:8 and hCðwÞiz30:0, respectively. Similarly, theBiophysical Journal 100(8) 2024–2032number of interpeptide hydrophobic contacts is reduced
from 5.4 in water to 3.4 in naproxen. This implies that nap-
roxen eliminates approximately one-third of interpeptide
interactions. The antiaggregation effect of naproxen appears
to increase with the decrease in temperature.
The impact of naproxen is further probed by computing
the free energy of Ab dimer, FðCÞ, as a function of the
number of interpeptide contacts C. Similar to the free energy
profiles we computed for the ligand-free (water) environ-
ment (45), FðCÞ features a single minimum attributed to
dimer state. The free energy of dimer formation is defined
as DFAD ¼ FA  FD, where FA and FD ¼ 0 are the free
energies of associated (A) and dissociated (D, C ¼ 0) states.
To compute FA we integrated the states with
FðCÞ%Fmin þ 1:0 RT, where Fmin is the minimum in
FðCÞ. When Ab peptides are coincubated with naproxen
at 360 K, DFADðnpxnÞ is z 6:1 RT compared to
DFADðwÞz 7:5 RT in water (45). Therefore, naproxen
interactions reduce the free energy of dimer formation by
DDFAD ¼ DFADðnpxnÞ  DFADðwÞz1:4 RT. Consis-
tent with the growing gap between hCðTÞi and hCðT;wÞi
in Fig. 2, at 330 K, DDFAD increases to 5:4 RT.
Structural changes in Ab oligomer induced by naproxen
can be revealed by computing the radial number density
GðrÞ of Ab atoms as a function of the distance to the olig-
omer center of mass r. Fig. 3 a shows that GðrÞ remains
relatively constant at r(10 A and then sharply declines.
Consequently, we define the dimer core, in which the atomic
density is approximately constant, using the condition
GðrcÞ ¼ 0:7Gð0Þ, where rc is the core radius. We found
that at 360 K rc ¼ 12 A. To study the changes in the dimer
size, the inset to Fig. 3 a displays the temperature depen-
dences of the core volumes computed for naproxen solution
and water (49), VcðTÞ and VcðT;wÞ, respectively. At
T(400 K, the Ab dimer coincubated with naproxen
expands compared to the ligand-free environment. For
instance, Vc exceeds VcðwÞ by ~30% at 360 K. The reason
FIGURE 4 Difference contact map hDCði; jÞi shows changes in the prob-
abilities of interpeptide contacts between residues i and j in Ab dimer at
360 K. Values of hDCði; jÞi are color coded according to the scale. The inset
displays the numbers of interpeptide contacts formed by residues i in Ab
dimer: hCdðiÞi(in black) for naproxen solution, hCdði;wÞi(in gray) for
water. The Nt and Ct terminals are boxed. These plots reveal that naproxen
weakens interpeptide interactions, but does not shift the dimer aggregation
interface, which is still centered in the Nt.
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FIGURE 3 (a) Normalized radial number density GðrÞ of Ab atoms as
a function of the distance to the dimer center of mass r at 360 K. Dotted
line marks the level of 0:7Gð0Þ used to define the dimer core. Inset shows
the temperature dependence of the core volume: VcðTÞ(in black) for nap-
roxen solution, VcðT;wÞ(in gray) for water. (b) Peptide atom number
density in the core as a function of temperature: ncðTÞ(black solid circles)
for naproxen solution, ncðT;wÞ(gray circles) for water. Ligand atom
number density ncðT; npxnÞ in the core is shown by open circles. Inset
displays the fraction of peptide atoms in the dimer core FcðTÞ versus
temperature: naproxen solution (solid black circles), water (gray circles).
The fraction of ligand atoms in the core FcðT; npxnÞ is shown by open
circles. The figure indicates that the dimer expansion is accompanied by
the drop of peptide atom density and penetration of ligands into its core.
Antiaggregation Effect of Naproxen 2027for dimer swelling can be gleaned from Fig. 3 b. The inset
shows the fractions of Ab atoms FcðTÞ in the dimer core
as a function of temperature in naproxen solution and water.
This plot suggests that FcðTÞ is not affected by naproxen.
However, if one considers the average peptide atom number
density in the core computed for naproxen solution and
water, ncðTÞ and ncðT;wÞ, it then becomes clear that ncðTÞ
is reduced ~25% compared to water at 360 K (Fig. 3 b).
We observe from Fig. 3 b that the decrease in peptide
atom density is accompanied by the increase in the ligand
atom density in the core ncðT; npxnÞ, i.e., by the influx of
ligands into the dimer volume. Specifically, the inset to
Fig. 3 b demonstrates that 32% of naproxen molecules
(FcðnpxnÞ ¼ 0:32) are localized in the dimer core at 360 K.
Therefore, expansion of the dimer is caused by penetration
of ligands into its core.To investigate the impact of naproxen on the dimer aggre-
gation interface, we analyzed the difference contact map
hDCði; jÞi, which shows the changes in the probabilities of
interpeptide contacts formed by residues i and j in naproxen
solution relative to water. Fig. 4 shows that naproxen either
reduces the probability of interpeptide contacts or leaves
them intact. The inset to Fig. 4 compares the number of
interpeptide contacts, hCdðiÞi and hCdði;wÞi, formed by
residues i in Ab dimer in naproxen solution and water,
respectively. The naproxen weakens interpeptide interac-
tions in both the Nt and Ct terminals. For example, the total
numbers of interpeptide contacts in the Nt and Ct are
reduced by 5.1 (a 32% decrease with respect to water value)
and 3.3 (a 38% decrease), respectively. The largest
decreases in contact numbers are observed for Phe20,
Phe19, and Tyr10. However, naproxen interference does
not change the location of Ab aggregation interface. Specif-
ically,<CdðNtÞ> ¼ 11:0 and<CdðCtÞ> ¼ 5:3 interpeptide
contacts in naproxen solution are formed by Ab Nt and Ct
terminals. For comparison, in water the corresponding
numbers are 16.1 and 8.6. Therefore, in both environments
hCdðNtÞi=hCdðCtÞiz2 indicating that about two-thirds of
interpeptide interactions are localized in the Nt terminal,
i.e., this sequence region is the primary aggregation inter-
face in water and in naproxen solution. Furthermore, this
point can be illustrated if one considers the probability
PcðiÞ for amino acid i to occur in the dimer core of the radius
rc. Fig. S3 shows that PcðiÞ and Pcði;wÞ computed for
naproxen solution and water (49) are remarkably similar.
For example, in naproxen solution at 360 K the average Pc
for the residues in the Nt and Ct are 0.57 and 0.35. The
same quantities computed for water are 0.57 and 0.40
(49). Hence, in both environments the Nt terminal is typi-
cally buried in the dimer core, whereas the Ct is exposed.Biophysical Journal 100(8) 2024–2032
a2028 Kim et al.The changes in secondary structure induced by naproxen
are assessed by computing the fractions of b-strand and
helix residues, hSi and hHi, at 360 K. In naproxen solution,
hSi and hHi are 0.40 and 0.18 compared to 0.37 and 0.21 in
water (45). The largest change in secondary structure is
observed in the Nt, where the strand content hSðNtÞi
increases from 0.36 in water to 0.44 in naproxen solution.
Simultaneously, hHðNtÞi is decreased from 0.32 to 0.25.
However, on average naproxen induces conformational
change in only two residues in Ab peptide within the dimer,
so its secondary structure remains largely unchanged.b
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FIGURE 5 (a) Probability of naproxen molecule binding to Ab dimer,
PbðTÞ, as a function of temperature. Binding temperature Tb is associated
with the midpoint of PbðTÞ. Inset shows the number of naproxen ligands
bound to Ab dimer hLi (continuous line) and the number of ligands bound
to Ab aggregation interface hLii (dashed line) versus temperature. (b) Free
energy FðrbÞ of naproxen as a function of the distance between ligand and
Ab dimer, rb (solid circles). The free energy of binding DFb is computed
by integrating over the ligand bound states with FðrbÞ%Fmin þ 1:0 RT,
where Fmin is the minimum in FðrbÞ. The values of F at rb>29 A˚ are set
to zero and correspond to unbound state. Free energies FðrbÞ describing
naproxen binding to Abmonomer and fibril computed earlier (35) are given
by open circles and squares, respectively. Inset: Radial distribution functions,
gppðrÞ and glpðrÞ, map minimum distances between amino acids from
different peptides and between ligands and amino acids, respectively. The
functions gppðrÞ obtained in water and naproxen solution are shown by
continuousgray andblack lines; the functionglpðrÞ is representedbyadashed
line. All plots in (b) are obtained at 360 K. The figure implies that naproxen
binds to Ab dimer and interferes with interpeptide interactions.Naproxen binding to Ab dimer affects interpeptide
interactions
Destabilization of Ab dimer by naproxen suggests binding of
this ligand to Ab. To examine naproxen-Ab interactions, we
plot the probability of naproxenmolecule binding toAbdimer,
Pb (Fig. 5 a). Defining the binding temperature Tb from the
condition PbðTbÞ ¼ 0:5, we find Tb ¼ 380 K; because at
360 K Pbz0:71, the average number of bound ligands is
hLiz14:2 (out of the total of 20). It is important that ~45%
of the bound ligands (hLiiz6:3) interferewith the interpeptide
interactions as they bind simultaneously to both peptides in
the dimer (inset to Fig. 5 a). Given that the total number of
contacts between naproxen and Ab dimer is hCliz58:8,
each bound naproxen ligand interacts with roughly four amino
acids. Interestingly, the contribution of ligand-Ab HBs to
binding is small. For example, the total number of HBs
between the ligands and Ab dimer backbone at 360 K is
only hNlhbiz3:5, i.e., it is 16 times smaller than hCli.
As a quantitative measure of naproxen binding affinity we
use the binding free energy DFb, which is the difference
between the free energies of the bound and unbound states.
This can be obtained from the free energy FðrbÞ of a ligand
as a function of the distance between ligand and Ab dimer,
rb (Fig. 5 b). The profile of FðrbÞ displays a single minimum
at rbz5 A˚ attributed to the bound state, from which DFb is
found to be 6:8 RT.
Our simulations indicate that naproxen molecules pene-
trate the volume of Ab dimer and almost half impact the
dimer aggregation interface. Further illustration of the com-
petition between interpeptide amino acid interactions and
ligands-peptide contacts comes from the analysis of amino
acid and ligand radial distribution functions, gppðrÞ and
glpðrÞ (the inset to Fig. 5 b). It follows from gppðrÞ that a
contact distance between amino acids from different
peptides in water peaks at rz5 A. When coincubated with
naproxen, the amplitude of the gppðrÞ peak is reduced and
its tail extends to a larger r. Of importance, the function
glpðrÞ, which measures the distribution of contact distances
r between naproxen ligands and amino acids, reveals that a
typical r coincides with that observed for amino acid inter-
peptide contacts. The comparison of these functions
suggests that 1) a direct competition between interpeptideBiophysical Journal 100(8) 2024–2032amino acid and ligands-peptide interactions takes place
and 2) interpeptide amino acid contacts are suppressed
and the separation between amino acids grows (from 7.8
in water to 9:1 A in naproxen solution).Naproxen binding to Ab dimer is governed
by Ab sequence
It is important to establish the factors that control naproxen
binding to Ab dimer. To this end, we use a combination of
implicit solvent REMD and AutoDock simulations (see
Methods). Because the latter were performed at 330 K, we
report corresponding REMD data at the lower temperature
Antiaggregation Effect of Naproxen 2029of 330 K, which is closer to physiological regime. (As
emphasized above, naproxen binding propensities at 330
and 360 K are qualitatively similar.) We first analyze the
binding affinities of residues in Ab sequence. Fig. 6 a pres-
ents the number of contacts hClðiÞi formed by amino acid i
with the ligands. Despite noticeable fluctuations in hClðiÞi,
with i it is clear that the N-terminal forms contacts with nap-
roxen more frequently than the C-terminal. Specifically, the
Nt and Ct regions form 19.9 and 8.6 contacts, respectively,
or 1.4 and 0.8 contacts per residue. To check if ligand
binding is driven by the interactions with side chains, we
plot in Fig. 6 a the energies of interactions between amino
acid i and ligands hEbðiÞi. This figure reveals a strong corre-
lation between hClðiÞi and hEbðiÞi (the correlation factor is
0.94). Consistent with the distribution of ligand-residue
contacts hClðiÞi the N-terminal forms significantly stronger
interactions with naproxen than the Ct. For example, thea
b
FIGURE 6 (a) Number of contacts hClðiÞi formed by amino acid i in Ab
dimer with naproxen ligands (solid circles). Energy of interactions between
amino acid i and ligands hEbðiÞi are represented by open circles. Both quan-
tities are computed using REMD at 330 K and normalized. The Nt and Ct
terminals are boxed. (b) Probability PbðiÞ of naproxen binding to amino
acid i in Ab monomer computed using AutoDock: WT Ab (solid circles),
reversed Ab mutant (open circles, Fig. 1 b). Amino acid numbers for the
mutant sequence are shown on top in a backward direction (from 40 to
10). Both panels implicate ligand-amino acid interactions as a main factor
controlling the location of ligand binding sites along Ab sequence.average ligands-residue energy for amino acid in the Nt is
hEbðNtÞiz 4:1 kcal =mol, whereas the ligands-residue
interactions in the Ct are three times weaker (hEbðCtÞiz
1:3 kcal =mol). To check if the naproxen binding is
affected by the local secondary structure, we compared
the fractions of strand and helix structure for individual resi-
dues, hSðiÞi and hHðiÞi, with hClðiÞi. The absolute values of
correlation coefficients computed for (hSðiÞi; hClðiÞi) and
(hHðiÞi; hClðiÞi) pairs are less than 0.1, suggesting that Ab
secondary structure has no impact on naproxen binding.
Our previous studies of naproxen binding to Ab fibrils
have determined that interligand interactions make a large
contribution to binding energetics (34). To probe the interac-
tions between naproxen molecules we examined the forma-
tion of ligand clusters bound to Ab dimer. A bound cluster
of the size Sc is defined as a group of Sc interacting ligands,
among which at least one is bound to Ab. The distribution
of the number of ligands hLðScÞi with respect to the cluster
size Sc is bimodal at 330 K (see Fig. S4). About 92% of
ligands are involved in large clusters (Sc>6) that implicates
strong interligand interactions. Indeed, for a bound naproxen
the average energy of ligand-ligand interactions is
hElliz 14:7 kcal =mol, whereas the energy of ligand-Ab
interactions is smaller (hElpiz 8:0 kcal =mol). To estab-
lish the roles of these interactions in binding to Ab, we
computed hElli and hElpi separately for the naproxen
molecules bound to the Nt and Ct regions. The average
ligand-ligand energies hElli for naproxen molecules bound
to the Nt and Ct are similar (<DEll> ¼ <EllðNtÞ>
EllðCtÞ>z 1:0 kcal =mol). In contrast, the correspond-
ing difference in the ligand-Ab energy hDElpi is three-fold
larger (3:3 kcal =mol) consistent with the computations
of ligands-residue interactions in Fig. 6 a.
Our results suggest that the interactions between nap-
roxen ligands and Ab side chains determine the distribution
of naproxen along the Ab sequence. To provide an addi-
tional test for this conclusion, we use the AutoDock simula-
tions and consider the probability PbðiÞ of naproxen binding
to amino acid i in Ab monomer (see Methods). These
computations were performed for the wild-type (WT) Ab
sequence and the mutant, in which the order of amino acids
is reversed (Fig. 1 b). Reversed sequence is ‘‘fitted’’ into the
monomer structures (see SupportingMaterial). If binding of
naproxen to Ab is driven by the interactions with amino
acids, then the mutant profile PMb ðiÞ should also be reversed
as a function of i when compared to the WT PbðiÞ. To check
this assumption, Fig. 6 b superimposes the WT and mutant
probability distributions PbðiÞ and PMb ðiÞ. It is clear that
both profiles are remarkably similar when the WT sequence
is compared with the backward counted mutant one (the
corresponding correlation coefficient is 0.91). These com-
putations together with the data presented above implicate
the interactions between ligands and amino acids as the
main factor controlling the distribution of naproxen binding
sites in Ab dimer.Biophysical Journal 100(8) 2024–2032
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Mechanism of naproxen antiaggregation effect
In this article, we have analyzed binding of naproxen to Ab
dimer, the smallest Ab oligomer. Our REMD simulations
indicate that naproxen binds to Ab dimer at temperatures
below Tb ¼ 380 K. Naproxen binding destabilizes, but does
not depolymerize Ab dimer. At 360 K naproxen interference
eliminates about one-third of the interpeptide interactions in
the dimer and reduces the free energy gain of dimer forma-
tion DFAD by DDFAD ¼ 1:4 RT, from 7.5 to 6:1 RT.
We further showed that about a third of all naproxen ligands
penetrate the core of Ab dimer, causing a 30% swelling of its
volume. Of importance, these structural changes result in
~25% drop of the peptide atom number density in the core.
Our simulations also suggest that close to half of the bound
ligands (45%) occur at the Ab dimer interface resulting in
a direct competition between ligand-amino acid and amino
acid-amino acid interactions (Fig. 5 b). Consequently, inter-
peptide side chain contacts are compromised. Direct interfer-
ence of ligands with interpeptide interactions has been also
observed for tricyclic planar ligands (50). MD simulations
have shown that 9,10-anthraquinone binding to Ab1420
peptide destabilizes the formation of interstrand HBs and
reduces the accumulation of ordered aggregates.
Comparison of the free energies of ligand binding and
dimer formation can explain why naproxen only destabilizes
Ab dimer. According to our previous simulations (34) the
free energy of naproxen binding to Ab monomer DFbðmÞ
is 5:1 RT (Fig. 5 b). This value should be compared with
the free energy of dimer formation in water, which is
DFADðwÞ ¼ 7:5 RT (45). Therefore, the affinity of Ab
peptide with respect to binding naproxen is weaker than
for binding another Ab chain.
An interesting question pertains to the comparison of
antiaggregation propensity of naproxen against Ab dimers
and fibrils. Recently, we have studied the growth of Ab
amyloid fibril in naproxen solution and compared it with
the ligand-free environment (35). It has been shown that
naproxen reduces the free energy of Ab binding to the fibril
DFBU by DDFBU ¼ 5:2 RT, from 9.9 in water to
4:7 RT in naproxen solution. In contrast, at the same
conditions and for the same ligand:peptide ratio naproxen
reduces the dimer aggregation free energy to DFAD ¼
6:1 RT (i.e., only by 1:4 RT as shown above). Therefore,
in naproxen solution Ab dimer has lower free energy than
Ab peptide bound to amyloid fibril. It is also worth noting
two other observations. First, the free energy of naproxen
binding to Ab monomer DFbðmÞ ¼ 5:1 RT is higher
than that of ligand binding to Ab fibril (DFbðf Þ ¼
7:6 RT, Fig. 5 b) (34). Second, due to naproxen the
number of peptide-fibril side chain contacts is reduced by
14.9 (35), whereas the number of interpeptide contacts in
the dimer is reduced by 10.2. These findings imply that nap-
roxen works as a better antiaggregation agent against AbBiophysical Journal 100(8) 2024–2032fibrils than against oligomers. It is also expected that,
although the decrease in naproxen concentration will
weaken its antiaggregation propensity, the relative antiag-
gregation efficiency against Ab fibrils and oligomers will
not change.
Our REMD simulations suggest that naproxen does not
change aggregation interface of Ab dimer. This inference
is based on two results. First, as in water (45) the aggregation
interface primarily involves the AbNt terminal, which forms
about two-thirds of the interpeptide interactions (Fig. 4).
Second, the spatial distributions of amino acids in the dimer
volume PcðiÞ reveal the same propensities for the Nt and Ct
terminals to occur in the dimer core in both environments
(Fig. S3) (49). As a rule the core is formed by the Nt, whereas
the Ct is mainly found on the dimer surface. Furthermore,
our analysis indicates that naproxen binding does not change
the distribution of Ab dimer conformational clusters com-
pared to water environment (45). This observation is likely
the result of the lack of correlation between the Ab
secondary structure and naproxen binding.
Finally, it is interesting to comment on the secondary
structure changes induced by naproxen in different Ab
species. Naproxen appears to make minor changes in
b-strand and helix contents in the dimer (<15%, see Results)
and in Ab peptides bound to the fibril (<6%) (35). In
contrast, naproxen induces a shift in the monomer confor-
mational ensemble, increasing the b content by 50% and
decreasing the helix population by a third (35). Thus, nap-
roxen binding has a noticeable impact on the Ab monomer
conformations, but small on aggregated species.Naproxen binds to Ab dimers and fibrils via
different mechanisms
Are the mechanisms of naproxen binding to Ab dimers and
fibril different? Our previous studies of naproxen interac-
tions with Ab fibrils (34) and the current work allow us to
examine this question. Ab fibril features concave (CV)
and convex (CX) edges, which have different binding affin-
ities for naproxen. The number of ligands bound to the CV
edge, which has a groove, is more than twice larger than the
number of ligands attracted to the CX with a protruding
surface. Of importance, the energies of ligand-fibril interac-
tions are similar for the CX and CV edges. In contrast, the
energy of ligand-ligand interactions for the CV is
5:5 kcal =mol lower compared to the CX edge. As a result
binding to the CV edge is energetically preferred. We
showed previously that the enhancement of interligand
interactions on the CV edge is the result of the confinement
effect of the groove, which induces the formation of large
clusters of bound ligands (34,51). At 360 K ~90% of bound
naproxen molecules participate in the formation of large
clusters (Sc>6). This previous energetics analysis together
with the computational study of thioflavin-T binding (52)
showed that the location of ligand binding sites on amyloid
Antiaggregation Effect of Naproxen 2031fibril is mainly determined by its surface geometry, rather
than by sequence.
Study of naproxen binding to Ab dimer also reveals
strong intermolecular interactions formed between bound
naproxen ligands. For example, the energy of ligand-ligand
interactions hElli is approximately two times lower than the
ligand-Ab interaction energy hElpi. Furthermore, on an
average 92% of ligands form large clusters bound to Ab
dimer. These aspects of naproxen binding to Ab dimer are
similar to the fibril binding. The difference is the interac-
tions between the ligands and amino acids in Ab dimer
appear to control the location of binding sites. There are
three lines of evidence to this conclusion. First, the change
in the energy of interligand interactions hElli along the Ab
sequence is three times smaller than the corresponding vari-
ation in the energy of ligand-residue interactions hElpi.
Second, Fig. 6 a strongly suggests that the distribution of
ligand binding sites along the Ab sequence is determined
by the energies of interactions between ligands and amino
acids. Third, the distributions of bound ligands along the
WT and reversed Ab sequences are in close agreement
when the reversed sequence is considered in the backward
direction (Fig. 6 b). These observations imply that the
binding sites follow the sequence of amino acids. On the
basis of our analysis, we argue that the preferential binding
location of naproxen in Ab dimer is the N-terminal, which is
also the primary aggregation interface. This circumstance
contributes to the antiaggregation propensity of naproxen.
Because Ab dimer has fluid structure, the formation of
stable grooves is unlikely. Therefore, even though naproxen
forms attractive interligand interactions upon binding to Ab
dimer, these interactions cannot determine the location of
binding sites as it occurs for Ab fibril. The arguments pre-
sented above suggest that the mechanisms of naproxen
binding to Ab oligomers and fibrils are different.Comparison with experiments
It is important to compare our in silico findings with avail-
able experimental data. We are not aware of the experiments
that have specifically investigated the impact of naproxen on
Ab oligomers. However, studies of other ligands may
provide important insights into naproxen antiaggregation
potential. For example, the effect of curcumin, a ligand
with two phenyl rings, on Ab aggregation has been studied
(53). It has been demonstrated that curcumin completely
blocks Ab oligomer formation at the ligand to the Ab stoi-
chiometric ratio of 3:1. It was also reported that curcumin
reduces but does not prevent fibril formation. Furthermore,
according to the experiments curcumin inhibits Ab cytotox-
icity at the stoichiometric ratio of 10:1. Based on the com-
parison of the concentrations of curcumin and naproxen,
which achieve the same inhibition of Ab aggregation, the
latter was found to be a four times less potent antiaggrega-
tion agent than curcumin.It seems likely that the reason for relative inefficiency of
naproxen compared to curcumin is its weaker antiaggrega-
tion propensity against Ab oligomers compared to that
against Ab fibrils. Recent experiments indicate that such a
mode of antiaggregation is not optimal for blocking Ab
cytotoxicity. For example, Hecht and co-workers have found
that the ligands, which provide the strongest inhibition of
cytotoxicity, are those that accelerate fibril formation (54).
Compared to naproxen these compounds are likely to reduce
more efficiently the concentration of Ab oligomers, which
are the primary cytotoxic Ab species as shown in recent
mutagenesis studies with murine models (9). In contrast,
according to our data naproxen destabilizes less cytotoxic
Ab fibrils to a greater extent than the most cytotoxic Ab
oligomers. This antiaggregation effect may even be counter-
productive as it may raise the concentration of oligomeric
species. Therefore, according to our study the limitations
of naproxen as an antiaggregation agent are that 1) it targets
Ab fibrils rather than oligomers and 2) it destabilizes but
does not dissociate Ab aggregates. These circumstances
might be the reasons for naproxen moderate efficiency as
prophylactic therapeutic agent in AD, and its failure to
reverse preexisting AD conditions (12,15).SUPPORTING MATERIAL
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